Literature DB >> 17055023

A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein.

Shixing Tang1, Sherimay Ablan, Megan Dueck, Wilfredo Ayala-López, Brenda Soto, Margaret Caplan, Kunio Nagashima, Indira K Hewlett, Eric O Freed, Judith G Levin.   

Abstract

The HIV-1 capsid (CA) protein plays an important role in virus assembly and infectivity. Previously, we showed that Ala substitutions in the N-terminal residues Trp23 and Phe40 cause a severely defective phenotype. In searching for mutations at these positions that result in a non-lethal phenotype, we identified one candidate, W23F. Mutant virions contained aberrant cores, but unlike W23A, also displayed some infectivity in a single-round replication assay and delayed replication kinetics in MT-4 cells. Following long-term passage in MT-4 cells, two second-site mutations were isolated. In particular, the W23F/V26I mutation partially restored the wild-type phenotype, including production of particles with conical cores and wild-type replication kinetics in MT-4 cells. A structural model is proposed to explain the suppressor phenotype. These findings describe a novel occurrence, namely suppression of a mutation in a hydrophobic residue that is critical for maintaining the structural integrity of CA and proper core assembly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055023      PMCID: PMC1851891          DOI: 10.1016/j.virol.2006.09.027

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  66 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Retrovirus capsid protein assembly arrangements.

Authors:  Keith Mayo; Doug Huseby; Jason McDermott; Brian Arvidson; Liam Finlay; Eric Barklis
Journal:  J Mol Biol       Date:  2003-01-03       Impact factor: 5.469

4.  The stoichiometry of Gag protein in HIV-1.

Authors:  John A G Briggs; Martha N Simon; Ingolf Gross; Hans-Georg Kräusslich; Stephen D Fuller; Volker M Vogt; Marc C Johnson
Journal:  Nat Struct Mol Biol       Date:  2004-06-20       Impact factor: 15.369

5.  Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange.

Authors:  Jason Lanman; TuKiet T Lam; Mark R Emmett; Alan G Marshall; Michael Sakalian; Peter E Prevelige
Journal:  Nat Struct Mol Biol       Date:  2004-06-20       Impact factor: 15.369

6.  Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.

Authors:  T Fitzon; B Leschonsky; K Bieler; C Paulus; J Schröder; H Wolf; R Wagner
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

7.  Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag.

Authors:  S J Rulli; D Muriaux; K Nagashima; J Mirro; M Oshima; J G Baumann; A Rein
Journal:  Virology       Date:  2006-01-19       Impact factor: 3.616

8.  A conformational switch controlling HIV-1 morphogenesis.

Authors:  I Gross; H Hohenberg; T Wilk; K Wiegers; M Grättinger; B Müller; S Fuller; H G Kräusslich
Journal:  EMBO J       Date:  2000-01-04       Impact factor: 11.598

9.  Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag.

Authors:  Chen Liang; Jing Hu; Rodney S Russell; Ariel Roldan; Lawrence Kleiman; Mark A Wainberg
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  LuSIV cells: a reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication.

Authors:  J W Roos; M F Maughan; Z Liao; J E Hildreth; J E Clements
Journal:  Virology       Date:  2000-08-01       Impact factor: 3.616

View more
  6 in total

1.  The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability.

Authors:  Jiyang Jiang; Sherimay D Ablan; Suchitra Derebail; Kamil Hercík; Ferri Soheilian; James A Thomas; Shixing Tang; Indira Hewlett; Kunio Nagashima; Robert J Gorelick; Eric O Freed; Judith G Levin
Journal:  Virology       Date:  2011-10-26       Impact factor: 3.616

2.  Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein.

Authors:  Weifeng Wang; Jing Zhou; Upul D Halambage; Kellie A Jurado; Augusta V Jamin; Yujie Wang; Alan N Engelman; Christopher Aiken
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 3.  HIV-1 uncoating: connection to nuclear entry and regulation by host proteins.

Authors:  Zandrea Ambrose; Christopher Aiken
Journal:  Virology       Date:  2014-02-20       Impact factor: 3.616

4.  Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail.

Authors:  Melissa V Fernandez; Huxley K Hoffman; Nairi Pezeshkian; Philip R Tedbury; Schuyler B van Engelenburg; Eric O Freed
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

5.  Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function.

Authors:  Ferenc Tóth; János Kádas; János András Mótyán; József Tőzsér
Journal:  FEBS Open Bio       Date:  2016-06-30       Impact factor: 2.693

6.  The KT Jeang Retrovirology prize 2018: Eric Freed.

Authors: 
Journal:  Retrovirology       Date:  2018-07-02       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.